Related Experiment Video
Updated: Sep 3, 2025
Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
Published on: June 18, 2013
Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy
Wenjing Xu1, Chunping Ye2, Xin Qing1
1School of Medicine, Southeast University, Nanjing, 210009, China.
Abstract:
Multi-target Tyrosine Kinase Inhibitors (MTKIs) have drawn substantial attention in tumor therapy. MTKIs could inhibit tumor cell proliferation and induce apoptosis by blocking the activity of tyrosine kinase. However, the toxicity and drug resistance of MTKIs severely restrict their further clinical application. The nano pharmaceutical technology based on MTKIs has attracted ever-increasing attention in recent years. Researchers deliver MTKIs through various types of nanocarriers to overcome drug resistance and improve considerably therapeutic efficiency. This review intends to summarize comprehensive applications of MTKIs nanoparticles in malignant tumor treatment. Firstly, the mechanism and toxicity were introduced. Secondly, various nanocarriers for MTKIs delivery were outlined. Thirdly, the combination treatment schemes and drug resistance reversal strategies were emphasized to improve the outcomes of cancer therapy. Finally, conclusions and perspectives were summarized to guide future research.
Insights
Multi-target tyrosine kinase inhibitors (MTKIs) show promise in cancer treatment by blocking tumor growth. Nanoparticle delivery of MTKIs enhances efficacy and overcomes resistance, improving cancer therapy outcomes.
Area of Science:
- Oncology
- Nanomedicine
- Pharmacology
Background:
- Multi-target tyrosine kinase inhibitors (MTKIs) are crucial in cancer therapy, inhibiting tumor cell proliferation and inducing apoptosis.
- Clinical application of MTKIs is limited by toxicity and drug resistance.
- Nanoparticle-based drug delivery systems offer a promising approach to overcome these limitations.
Purpose of the Study:
- To review the applications of MTKIs nanoparticles in malignant tumor treatment.
- To summarize the mechanisms, toxicity, and nanocarrier systems for MTKIs.
- To highlight combination therapies and resistance reversal strategies for improved cancer outcomes.
Main Methods:
- Literature review of MTKI nanoparticle applications in cancer therapy.
- Analysis of MTKI mechanisms, toxicity profiles, and nanocarrier systems.
- Examination of combination treatment schemes and drug resistance reversal strategies.
Main Results:
- MTKIs effectively inhibit tumor growth but face challenges with toxicity and resistance.
- Various nanocarriers (e.g., liposomes, nanoparticles) enhance MTKI delivery and therapeutic efficiency.
- Combination therapies and resistance reversal strategies show potential for improved clinical outcomes.
Conclusions:
- MTKI-loaded nanoparticles represent a significant advancement in cancer treatment, addressing key limitations of conventional MTKIs.
- Further research into optimized nanocarrier design, combination therapies, and resistance mechanisms is essential.
- This review provides a comprehensive overview to guide future research in MTKI-based nanomedicine for oncology.
Related Concept Videos
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...